Pfizer vaccine, which early data found to be 90 percent effective, enrolled patients in Yale trials

Pfizer and BioNTech — the pharmaceutical companies currently leading a phase 3 coronavirus vaccine trial, in which efficacy and safety tests are being conducted — issued a press release explaining how their vaccine candidate had prevented COVID-19 transmission in over 90 percent of enrolled volunteers. Approximately 250 volunteers were enrolled in the Pfizer trials through a partnership between the Yale New Haven Hospital and the Yale Center for Clinical Investigation, according to Chief Medical Officer of the Yale New Haven Hospital Thomas Balcezak. At Yale, associate professor of medicine Onyema Ogbuagu is currently leading this study, as well as other clinical trials for COVID-19 therapies. Approximately 43,500 people around the world are participating in the Pfizer vaccine trials — half of whom have received the actual vaccine and half of whom were injected with a placebo. Out of all enrollees, there were 94 confirmed cases of COVID-19 infection thus far, with...